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Abstract
Background: Various microbial, inflammatory and immune signals regulate the activation of
dendritic cells (DC), determining their ability to interact with naïve T cells and to produce
cytokines that direct T cell development. In particular, CD40L and IL-1 cooperatively activate DC
to secrete high levels of IL-12. The immuno-stimulatory capacity of such DC is otherwise not well-
defined prompting further characterization of the effects of IL-1 and family members on DC
activation in comparison with other pro-inflammatory stimuli.
Results: Human DC co-activated in vitro by CD40L and IL-1 expressed numerous cytokine genes
including IL-12, IL-23 p19, IL-1, IL-1, IL-1Ra, IL-10, IL-6, IL-18 and IFN-. These DC produced
high levels of IL-12 protein and appeared capable of producing IFN-. Potent CD4+ and CD8+ T
cell-stimulatory properties were acquired by DC under conditions that also induced IL-12.
Notably, these DC induced rapid differentiation of fluMP-specific CD8+ T cells. Molecules related
to IL-1, like IL-1, co-induced IL-12 secretion whereas IL-18 did not. Conversely, the inhibitor IL-
1Ra, produced endogenously by DC curtailed IL-12 production in response to CD40L.
Conclusions: IL-1 and IL-1Ra play a biologically-relevant role in the positive and negative
regulation of DC activation. In conjunction with CD40L, IL-1 sends a powerful activation signal to
DC that could be distinguished from other modes of activation. This signal enables the production
of pro-inflammatory cytokines by DC, and enhances the differentiation of naïve T cells into
effectors of type-1 cellular immune responses.
Background
Dendritic cells (DC) are highly effective antigen present-
ing cells (APCs) capable of stimulating the differentiation
of naïve lymphocytes into effector cells (reviewed in [1]).
Specific properties of the DC determine the quality of im-
mune responses that they initiate. These properties are de-
termined by complex and dynamic changes both in the
DC and in its environment. Notably, DC undergo a so-
called process of maturation that changes migratory prop-
erties, diminishes antigen uptake, enhances antigen
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processing and presentation and induces the production
of an array of cytokines (reviewed in [2]). The qualitative,
quantitative and temporal regulation of cytokines pro-
duced by DC is thought to be a determining factor in the
development of immune responses initiated by these
APCs but molecules and mechanisms that regulate such
process are not entirely understood.
Activated T cells provide strong stimuli that activate cy-
tokine production in DC notably via interactions between
CD40L and CD40 [3,4]. This interaction not only regu-
lates the production of Th1 polarizing cytokines such as
IL-12 by DC in vitro but is a central event in vivo that ena-
bles DC to prime effective MHC class I-restricted CD8+ T
cell responses [5–7]. IL-12 is a pivotal factor for the initi-
ation of cellular immunity (reviewed in [8]). IL-12 pro-
motes the polarization of Th1 T cell development,
increases the differentiation and activation of cytolytic T
cells and in concert with IL-18, induces IFN- production
by T cells and NK cells. The mechanisms regulating IL-12
production are complex as IL-12 is composed of two
chains IL-12 (IL-12p35) and IL-12 (IL-12p40) with in-
dependent transcriptional regulation. The two chains as-
semble as a disulfide-linked heterodimer which is
glycosylated and secreted as a biologically active pro-in-
flammatory and immune mediator [9,10]. CD40L is
known to induce the production of high levels of IL-12
in human monocyte-derived DC [11]. Yet, signalling
through CD40 alone is not sufficient to induce the secre-
tion of substantial amounts of IL-12 heterodimer. We
and others have shown that a second signal, provided by
a microbial product (lipopolysaccharide=LPS) or by im-
mune mediators such as IFN- or IL-1, is required to in-
duce the secretion of high levels of IL-12 by DC in the
presence of CD40L [12–15].
IL-1 is major pro-inflammatory cytokine with multiple ac-
tivities in the regulation of immune, inflammatory, endo-
crine and neuronal systems (reviewed in [16]). The IL-1
family comprises several structurally-related ligands and
the most extensively characterized include IL-1, IL-1,
the inhibitory IL-1 receptor antagonist (IL-1Ra) and IL-18
(IL-1). These ligands bind to members of a family of re-
ceptors characterized by immunoglobulin folds in the ex-
tracellular portion and Toll/IL-1R (TIR) motif in the intra-
cytoplasmic portion [17]. Whereas ligands of Toll-like re-
ceptors such as LPS and other microbial products have re-
cently gained a lot of attention as regulators of immune
responses in general (reviewed by [18]) and of DC activa-
tion in particular [19], ligands of IL-1R family have not
been as extensively examined under this angle. On its
own, IL-1 is known to be a weak maturing agent for DC
[4]. However, we have recently shown that when com-
bined with CD40L, IL-1 sends a powerful cooperative
signal to monocyte-derived DC, inducing the secretion of
high levels of IL-12 [14]. This was recently confirmed and
extended to show that IL-1 and CD40L also induce the
secretion of high levels of IL-12 in CD34+ cell-derived DC
[15] and A. Wesa, unpublished observation), and that this
mode of activation also triggers the production of high
levels of IL-6 and the production of IL-1. The effects of IL-
1 can be explained at least at the transcriptional level, as
CD40L up-regulates IL-12 mRNA and IL-1 comple-
ments this effect by up-regulating IL-12 mRNA [14]. Our
own results suggest that CD40L co-activation with IL-1
yields high amounts of IL-12 but little IL-10 whereas LPS
induces IL-12 but also more IL-10 [14]. As DC encounter
various innate, microbial or immune stimuli that engage
distinct intracellular signaling pathways, it seems likely
that various combinations of these modes of activation
might not produce equivalent APCs. The immuno-stimu-
latory properties of DC activated with IL-1 and C40L have
not been well-defined and it is not clear that these cells
which produce high amounts of IL-12 will be able to
prime and activate naive T cells, in particular CD8+ T cells.
This prompted the present study to better characterize the
effects of IL-1 and to better understand the molecular reg-
ulation of DC function. We found that CD40L+IL-1
stimulation effectively confers immuno-stimulatory activ-
ity and could be distinguished from other modes of pro-
inflammatory activation of DC. We also found that the
constitutive expression of IL-1Ra in DC constitutes a regu-
latory mechanism curtailing DC activation in the absence
of specific inflammatory signals suggesting that the family
of IL-1 molecules has biological relevance to DC activa-
tion.
Results
Regulation of cytokine gene expression in DC
Cytokine gene expression in human monocyte-derived
DC was analyzed in response to various pro-inflammato-
ry stimuli. Immature DC were produced by culture of ad-
herent blood monocytes with GM-CSF and IL-4 and these
cells were matured by treatment with CD40L combined
with either IL-1 or IFN- or for comparison by treatment
with LPS+IFN- effective inducers of IL-12 in DC [12]. The
expression of IL-12, IL-12, IL-10, IL-1, IL-1, IL-1Ra,
IL-6, IL-18, IFN- and the housekeeping L32 and GAPDH
genes were assessed using a non-isotopic multiple probe
RPA. Levels of mRNAs were calculated in relation to
housekeeping gene expression. Results from 2 to 7 inde-
pendent experiments are presented in Figure 1. Treatment
with CD40L+IL-1 induced the expression of multiple
genes as IL-12, IL-10, IL-1, IL-1, IL-6, IL-18 and IFN-
were more highly expressed than in DC untreated or treat-
ed with IL-1 alone. The conjunction of CD40L with ei-
ther IL-1 or IFN- induced statistically higher levels of IL-
12 than CD40L alone (8.00  4.0 with CD40L+IL-1 or
5.68  1.6 with CD40L+IFN-; versus 1.53  .0.5 for
CD40L alone; p < 0.05). However, these two co-stimulato-
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ry signals had distinct effects. Treatment with
CD40L+IFN- induced IL-12, IL-1, IL-1, and low levels
of IL-18 but no IL-6, IL-10 or IFN-. Statistical analysis
confirmed that DC treated with CD40L+IFN- produced
significantly less IL-6, IL-10 and IL-1 than DC treated
with CD40L+IL-1 (p < 0.05, n = 3). This difference was
confirmed over time in kinetics studies examining gene
expression at 4, 8 and 16 hours post-stimulation (data not
shown). The overall strongest induction of gene expres-
sion was obtained by treatment with LPS+IFN- (Figure 1)
which was uniquely able to induce high levels of IL-12
mRNA by RPA. Furthermore, IL-1Ra mRNA was upregu-
lated in response to LPS+IFN- whereas it remained rela-
tively constant with all other stimuli.
As DC respond to complex signals including autocrine sig-
nals such as IL-1 and IFN-, it seemed imperative to ana-
lyze how these complex combinations regulate gene
expression in comparison with a strong pro-inflammatory
activator such as LPS. Combinations of CD40L, IFN-, LPS
and IL-1 were therefore compared (Figure 2). Each of the
combination tested induced the production of IL-12 and
the overall transcription profiles examined appeared to be
qualitatively similar. However, the presence of LPS clearly
correlated with higher levels of IL-12 and IL-10 mRNAs.
Thus, DC treated with CD40L+IL-1 induced gene expres-
sion patterns that were qualitatively similar to those in-
duced by LPS+CD40L, LPS+IL-1 or LPS+CD40L+IL-1
but qualitatively distinct from those induced by
CD40L+IFN-. This transcriptional analysis implies that
activation of DC by diverse pro-inflammatory agents may
have distinct functional outcome.
Regulation of IL-12 and IL-23 secretion in DC
We previously reported that IL-12  heterodimer was be-
ing secreted after stimulation with IL-1+CD40L [14]. To
verify these findings, supernatants of DC were immuno-
precipitated with a mAb against IL-12 and separated by
non-reducing SDS-PAGE. Detection with a mAb specific
for IL-12/ heterodimer (Figure 3-A) confirmed that
CD40L+IL-1, LPS+IFN-, and CD40L+IFN- induced the
secretion of the 70 kD heterodimer IL-12 at levels cor-
related to those detected by ELISA (data not shown).
These data confirmed the synergy of CD40L+IL-1+IFN-
on the secretion of IL-12/. The secretion of the 70 kD
IL-12 was further confirmed by blotting the immuno-pre-
cipitants with a polyclonal IL-12 Ab (Figure 3-B). This pol-
yclonal Ab also revealed the secretion of free IL-12 at 40
Figure 1
Comparison of different activation signals on gene
expression in DC. Normalized gene expression levels from
2–7 independent experiments with averages indicated by a
horizontal bar. DC were cultured with LPS+IFN- (n = 2);
CD40L+IFN- (n = 3); CD40L+IL-1 (n = 7); CD40L (n = 7);
IL-1 (n = 4); medium n = 4 for 8 hours and total RNA was
extracted and hybridized to biotin-labeled RNA probes.
After RNase treatment, digested probes were separated on a
5% acrylamide/8 M urea gel, blotted to a positively charged
membrane for detection with CDP-Star substrate solution,
and exposed to film or directly to the Kodak Image Station.
Controls include yeast RNA incubated with probes followed
or not by RNase treatment. Relative gene expression levels
were calculated by dividing the net intensity of a gene (calcu-
lated with Kodak 1D software) with the net intensity of L32
in the same lane.
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Figure 2
Effect of combined signals on cytokine gene expres-
sion in DC. DC (1  106) were treated with CD40L+IL-1,
CD40L+LPS, LPS+IL-1, LPS+CD40L+IL-1, CD40L+IFN-
or LPS+IFN- for 8 hours. Following stimulation, RNA was
isolated and subjected to RPA analysis (as described in Figure
1). Controls are shown of yeast RNA incubated with probes
followed by RNase treatment (background) or mock treat-
ment (undigested probes).
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kD in all conditions tested and the presence of a 60 kD
complex in some conditions (arrow). It is very likely that
this 60 kD complex formed between IL-12 (40 kD) and
the recently described p19 subunit chain form the IL-23
heterodimer [20]. RT-PCR confirmed that p19mRNA was
found in DC stimulated with CD40L and IL-1 (Figure 3-
C) and the detection of IL-23 in CD40L-activated DC is
consistent with prior reports [20]. Interestingly, immuno-
precipitation studies suggest that the IL-23 60 kD complex
is produced at a higher level upon treatment with
CD40L+IL-1+IFN-.
Production of IFN- by DC
RPA studies indicated that IFN- mRNA was induced after
stimulation of DC with CD40L+IL-1, CD40L+LPS or
LPS+IFN- (Figures 1 and 2). Production of IFN- has
been reported in murine DC [21] but not to our knowl-
edge in human DC. To verify these findings, we analyzed
the production of IFN- and IL-12 in DC by flow cytom-
etry. Results of 4 separate experiments showed the pres-
ence of intracellular IFN- as demonstrated by staining
levels above isotype-matched controls in cells of large
size, expressing HLA-DR or CD1a but lacking CD3 or
CD56 (Figure 4 and not shown). Under these conditions,
DC cultured in medium or with LPS or LPS+IL-1 did not
express significant levels of IFN- (data not shown), thus
arguing in favor of a specific response. Co-staining for
IFN- and IL-12p40 further showed that a subset of hu-
man monocyte-derived DC could produce both cy-
tokines. Statistical analysis showed that DC stimulated
with CD40L or CD40L+IL-1 (respectively containing 3.4
 2.5 % and 3.9  2.8 % cells expressing IFN-) produced
significantly more IFN- than control DC (0.08  0.1 %),
p < 0.05. This is consistent with mRNA data shown in Fig-
ure 1.
Regulation of cytokine production by molecules related to 
IL-1
IL-1, like other ligands of TLR/IL1R (LPS or peptidogly-
can) [19] is able to co-induce the secretion of IL-12
prompting us to ask if signaling through the IL-1R super-
family could represent a general mechanism for the induc-
tion of IL-12 in DC. Like IL-1, IL-1 acted in
combination with CD40L to increase the secretion of IL-
12 in a dose-dependent manner (Figure 5-A). Comparable
dose-response curves were obtained with IL-1 and IL-1
which at doses of 10 ng/ml co-induced the secretion of
14.9  3.8 and 13.0  4.3 pg IL-12/1000 cells, respectively,
while CD40L alone induced 0.3  0.4 pg IL-12/1000 cells
(n = 2). On the other hand, IL-18 showed no effect, even
at concentrations up to 500 ng/ml (Figure 5-A) as IL-
18+CD40L was not different from CD40L alone (1.12 
0.9 and 0.4  0.3 pg/1000 cells respectively, n = 2). While
IL-1 and IL-1 share the same signal-transmitting recep-
tor complex of IL-1RI and IL-1R3, IL-18 engages a distinct
receptor complex IL-1R5/IL-1R7 [17,22]. The expression
of IL-18R was undetectable on DC by flow cytometry, al-
though it was found on the surface of activated T cells (da-
ta not shown). The lack of responsiveness by DC to IL-18
appears to be due to the lack of IL-18R expression on
monocyte-derived DC.
Both unstimulated DC and activated DC constitutively ex-
pressed IL-1Ra mRNA. This IL-1 family member negative-
ly regulates IL-1 by competitively binding to IL-1RI
without inducing the signaling cascade (reviewed in [23]).
This suggested that IL-1Ra could perturb the effects of IL-
Figure 3
CD40L+IL-1-treated DC secrete IL-12 and IL-23
heterodimersA-B. Immature DC were stimulated for 24
hours with LPS+IFN-, CD40L+IFN-, CD40L+IL-1+IFN-,
CD40L or CD40L+IL-1. Supernatants and control AIM-V
medium were concentrated by centrifugation, then subject to
immunoprecipitation with anti-IL-12p40/p70 monoclonal
antibody (clone C8.6, PharMingen) and A/G agarose beads.
Immunoprecipitants were separated by 10% SDS PAGE
under non-reducing conditions. A. Detection of IL-12p70
using IL-12p70-specific rat mAb 20C2 (PharMingen). B.
Detection using anti-IL-12 polyclonal goat Ab (R&D Sys-
tems). C. RT-PCR analysis for p19 and 18s RNA. DC were
stimulated with indicated stimuli for 8 h. Total RNA was
extracted, reverse-transcribed and used as template for
amplification during 35 cycles. Results show ethidium bro-
mide detection of PCR products on agarose gel (represents
one of 3 separate experiments).
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1 signaling in DC and could impact on the regulation of
IL-12 production. Figure 5-B shows a representative exper-
iment with the specific inhibition of IL-1Ra by neutraliz-
ing antibodies. Anti-IL-1Ra Ab significantly increased the
secretion of IL-12 induced by CD40L relative to DC treat-
ed with control IgG and CD40L (4.65  3.7 and 0.85  0.7
respectively; p < 0.02, n = 3). The neutralizing anti-IL-1Ra
antibody did not affect the production of IL-12 when DC
were activated with medium or IL-1 alone which is con-
sistent with the fact that these conditions do not up-regu-
late IL-12 on their own. The neutralizing antibody also
did not affect the levels of IL-12 produced in response to
CD40L+IL-1. In this case, the exogenous IL-1 provided
maximal induction of IL-12 and was probably largely in
excess of the endogenous IL-1Ra, therefore inhibition of
IL-1Ra did not provide additional induction of IL-12. Al-
together, these results provide evidence that both IL-1Ra
mRNA and IL-1 mRNA are translated in CD40L-treated
DC, and act in a biologically relevant manner. Further,
this demonstrates that constitutive IL-1Ra expression reg-
ulates the response of DC to endogenous IL-1.
DC stimulated by CD40L+IL-1 effectively prime and stim-
ulate the differentiation of CD4+ and CD8+ T cells
DC treated with CD40L+IL-1 produced high levels of
pro-inflammatory cytokines such as IL-12 and IL-23 that
are known to augment T cell activation but also produce
inhibitory molecules such as IL-10 or IL-1Ra with oppo-
site effects. To assess the net outcome of this stimulation,
T cell-stimulating properties of these DCs were examined
using priming of naïve cord blood CD8+ T cells to the
HLA-A2-restricted fluMP peptide. The detection of fluMP-
specific cells in culture was done by flow cytometry using
Flu-MP-HLA-A2 tetramers. DC activated with CD40L+IL-
1 appeared to prime more effectively than DC activated
with CD40L or than immature DC (Table 1 and Figure 6-
A). Absolute numbers of tetramer-positive cells induced
by CD40L+IL-1-primed DC are significantly higher than
Figure 4
Production of IFN- by human monocyte-derived DC
DC were treated with CD40L (top left panel) or CD40L+IL-
1 (top right panel) for 24 hours, monensin being present
during the last 5 hours of incubation. After staining for sur-
face markers and intracellular IFN-, DC were analyzed by
flow cytometry. Large CD3- cells were analyzed (as shown in
gate represented in bottom left dot-plot) to exclude T cells,
and results show staining above isotype control (bottom
right dot-plot), being expressed as percentages of CD1a+
cells expressing IFN-. Result representative of 4 experi-
ments.
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Figure 5
Effects of IL-1 family membersA, IL-12 secretion is
modulated by IL-1 or IL-1, but not by IL-18. Human
monocyte-derived DC were treated with CD40L (1 g/ml)
for 24 hours in the presence of increased concentrations of
IL-1, IL-1 or IL-18 (0 to 100 or 500 ng/ml). Secreted IL-12
heterodimer was measured in supernatants by ELISA. B,
Blocking IL-1Ra increases CD40L-induced secretion of IL-12
heterodimer. DC were activated as indicated in the presence
of either anti-IL-1Ra neutralizing Ab or normal goat IgG for
24 hours. Supernatants were harvested and analyzed for IL-
12 heterodimer by ELISA. The average secretion in duplicate
wells was calculated as pg/1000 cells. Results are representa-
tive of three experiments. * indicates statistical significance of
anti-IL-1Ra Ab treatment.
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in cultures primed by CD40L-activated DC (p < 0.05, t
test). These enhancing effects of CD40L + IL-1 over
CD40L were blocked by polyclonal Abs to IL-12 recogniz-
ing IL-12-associated proteins suggesting that the en-
hanced production of IL-12 and/or IL-23 is responsible
for this activity (Table 1, experiment 4). Strikingly, pep-
tide presentation by DC matured with CD40L+IL-1 in-
duced the rapid differentiation of antigen-specific cells as
seen by the presence of Flu-MP-HLA-A2high CD45RA-
CD8+ T cells (Figure 6-B). This was confirmed at day 14
post priming (data not shown). Induction of allogeneic
responses was examined by measuring the production of
IFN- in MLR. Naïve cord blood CD4+ or CD8+ T cells or
adult blood T cells produced more IFN- when primed
with DC treated with CD40L+IL-1 than with DC treated
with CD40L alone or IL-1 alone (Figure 7). Thus, these
DC are highly effective and functional APCs that act in a
manner consistent with the production of high levels of
pro-inflammatory cytokines such as IL-12, IL-23, IL-18
and IFN- that are known to activate CD4+ and CD8+ T
cells and cellular immunity in general.
Discussion
We herein show that various pro-inflammatory molecules
can generate distinct activation profiles in DC and that
members of the IL-1 family of proteins play a biologically
relevant role in the regulation of the functional differenti-
ation of DC.
Multiple activation signals appear to be required to in-
duce the production of high levels of cytokines by DC.
The production of IL-12 which is a pivotal event in the de-
velopment of type-1 cellular immunity is effectively in-
duced in vitro by treating DC with CD40L+IL-1 and even
more so by CD40L+IL-1+IFN-, in agreement with recent
findings by Luft et al. [15]. Such synergistic concept is con-
sistent with in vivo studies showing the dependence on
both microbial signals and endogenous CD40L to induce
effective immunity [13]. Exposure to multiple pro-inflam-
matory mediators is likely to occur under biological cir-
cumstances as these mediators can be transcriptionally
induced in a contemporary manner and are regulated by
autocrine loops, commonly described in inflammation
[24]. In combination with CD40L, IL-1 induces the pro-
duction of IL-12, IL-1, IFN- and IL-18 in DC. IL-18, acting
in combination with IL-12 could induce large amounts of
IFN- by lymphocytes, further sensitizing DC to produce
extremely high levels of IL-12. The role played by DC-de-
rived IFN- remains unclear. Neutralization studies sug-
gest that IFN- is not responsible for IL-12 production in
Figure 6
CD40L+IL-1 stimulated DC are highly effective
APCs for CD8+ T cell priming. HLA-A2+ cord blood-
derived immature DC were treated with CD40L+IL-1,
CD40L or medium for 16 hours, pulsed with Flu-MP peptide,
washed and used to prime naïve autologous T cells. On day
7, T cell cultures were analyzed for the presence of antigen-
specific CD8+ T cells using Flu-MP-HLA-A2 tetramers. Rep-
resentative dot plots are shown of CD8 vs. Flu-MP tetramer
(A), and CD45RA vs. Flu-MP tetramer (gated on CD8+ cells)
(B). All were gated on live, PI- cells; quadrants were set
based on background staining with control mAbs. Percent
positivity is indicated in corresponding quadrants.
2.4
1.7
0.8
Medium
CD
8 
FI
TC
Flu-MP tetramer APC
CD40L
CD40L+
IL-1E
A.
2.0
0.4
1.6
0.1
0.8
0
CD
45
RA
 P
E
Gated on CD8+B.
Figure 7
CD40L+IL-1 stimulated DC induce high levels of
IFN- in MLR. DC were stimulated as indicated, then
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response to IL-1 and CD40L [14]. As IFN- is produced
approximately 24 hours after stimulation it seems that its
role would be to contribute to T cell activation rather than
to DC activation itself. DC-derived IFN- has been report-
ed in the mouse [21], albeit under distinct activating con-
ditions. Based on these studies it remains to be tested if
IFN- production by human DC might also be indirectly
due to the presence of IL-12 and IL-18.
Here, we report distinct pro-inflammatory stimuli that all
induce high levels of IL-12 but appear to provide other-
wise distinct responses. In contrast to IL-1, co-stimulation
with IFN- induced relatively little IL-10, IL-6, IL-18 and
IFN-. LPS induced higher IL-10, higher IL-1Ra and strik-
ingly less IL-23. The difference in the ability to produce IL-
10 was confirmed at the protein level (data not shown
and [14]). While IL-12 is important for naïve CD4+ T cell
priming, IL-23 is reportedly important for memory CD4+
cells [20]. Differences between IL-12 and IL-23 produc-
tion suggest that DC may display distinct cytokine profiles
that correspond to distinct phases of an immune re-
sponse. Another interpretation is that DC may interpret
distinct pathogen signals, for instance IL-1 or LPS, to
mount different types of cytokine reponses [19,25,26].
This would be desirable to optimize host defense against
particular aggressions or to be effective in particular tis-
sues. The biological consequences of these differences will
have to be determined in future studies.
An important aspect of the autocrine regulation of cy-
tokines in DC is the production of negative regulators
such as IL1Ra. Genetic invalidation of IL-1Ra not only up-
regulates inflammation but also affects the immune sys-
tem, causing spontaneous development of auto-immune
arthritis in certain strains of mice and rendering other
strains more susceptible to immunogens causing this dis-
ease [27]. The precise mechanisms underlying the role of
IL-1Ra in immune responses are complex, but implicate
antigen presentation. APCs of mice lacking IL-1Ra induce
higher proliferation and higher activation of wild-type
CD4+ T cells than control APCs, resulting in the up-regu-
lation of CD40L, OX40 and IL-2R, and thus have the op-
posite effects of APCs lacking IL-1 [28]. Our own data
provide a potential mechanistic explanation clearly show-
ing for the first time that IL-1Ra can have a direct role on
APC function by regulating the secretion of IL-12. Neu-
tralization experiments in DC showed that IL-1Ra inhibit-
ed the secretion of IL-12 in response to CD40L. This is
Table 1: Effects of DC activation on priming of CD8+ T cell responses
Exp. (a) DC used in priming (b) Percent of CD8+ cells binding 
Flu-MP-HLA-A2 tetramer
Absolute number of 
Flu-MP specific cells
Fold expansion Flu-MP 
specific T cells
1 CD40L + IL-1 2.39 5020 Not determined
CD40L 1.68 2900 "
Immature 0.84 1190 "
2 CD40L + IL-1 0.28 1400 7.0
CD40L 0.24 528 2.6
Immature 0.25 656 3.3
3 CD40L + IL-1 0.26 594 2.9
CD40L 0.14 309 1.5
Immature 0.00 0 0
4 CD40L + IL-1 IgG 1.39 2870 19.1
CD40L " 0.64 945 6.3
Immature " 0.61 1130 7.5
CD40L + IL-1 Anti-IL-12 0.57 1270 8.5
CD40L " 0.78 1200 8.0
Immature " 0.41 700 4.7
(a) Neonatal umbilical cord blood was used for exp. 1–3, adult mobilized peripheral blood was used in exp. 4. (b) Monocyte-derived DC cultured in 
GM-CSF+IL-4 were used as immature DC (unstimulated), or after activation with CD40L (1 ug/ml) or CD40L + IL-1 (1 ug/ml, 10 ng/ml respec-
tively) for 24 hours. In experiment 4, polyclonal neutralizing Abs to IL-12 or normal goat IgG (1 g/ml), were added at time of priming.
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most likely through negative regulation of endogenous IL-
1 responses as well as CD40L-induced IL-1 in DC. While
the RPA technique did not reveal IL-1 transcripts in un-
stimulated immature DC, it has been reported that IL-1
mRNA are detected by the more sensitive RT-PCR analysis
in freshly-isolated Langerhans cells, generally considered
a paradigm for unstimulated immature DC [29]. Further-
more, direct evidence of IL-1 protein secretion has been
shown in monocyte-derived DC [15]. This demonstrates
that autocrine cytokine regulation via IL-1 family mem-
bers is a biologically relevant mechanism in DC. As IL-1Ra
appears to be a negative regulator of DC activation, it is
notable that the LPS+IFN- stimulation induces the high-
est levels of IL-1Ra mRNA in DC. As high levels of IL-1,
IL-1 are also induced, IL-1Ra may provide a negative bal-
ance to prevent the establishment of an IL-1-mediated au-
tocrine stimulation cascade and to curtail the effects of
LPS. Thus, IL-1Ra may be one significant built-in mecha-
nism in the APC to regulate its immuno-stimulatory prop-
erties and to prevent the development of uncontrolled
immunity. The biological relevance of these conclusions
seems further supported by genetic analyses studies in hu-
mans. Polymorphisms in the IL-1Ra gene such as the
IL1RN*2 allele cause quantitative differences in both IL-
1Ra and IL-1 production and associate with the severity
of inflammatory and auto-immune diseases such as ulcer-
ative colitis and Crohn's disease, lupus erythematosus and
possibly with coronary artery disease. Conversely, these
polymorphisms negatively associate with various infec-
tions such as vaginal colonization with mycoplasmas, cy-
tomegalovirus, Epstein-Barr virus, human
immunodeficiency virus and with the occurrence of ovar-
ian cancer (recently reviewed in [30]).
Our results therefore identify IL-1 as an effective co-activa-
tor of DC in conjunction with CD40L. This is consistent
with the fact that IL-1 has been recognized as an adjuvant
for almost 2 decades [31] and may refine our understand-
ing of the effects of IL-1 in the context of DC-initiated im-
munity. Thus, IL-1 which is produced locally and
systemically in response to inflammation or infection
may play an important role as a T cell-independent factor
complementing the effects of T cell-derived CD40L. Upon
encountering these two molecules, DC would become
more effective APCs, producing IL-12, IL-23, IL-18 and
IFN- and stimulating the differentiation of CD4+ and
CD8+ T cells. Besides implications in inflammatory, infec-
tious or auto-immune diseases, our data are also consist-
ent with the identification of IL-1 as an important
adjuvant of CTL immunization in vivo in conjunction with
IL-12, IL-18 or IFN- [32]. Like IL-1, IL-12 is not critically
required for the generation of CTL, yet the addition of ex-
ogenous IL-12 or the inhibition of IL-12 respectively im-
prove or inhibit the development of CTL [33,34]. Our
results confirm that IL-12 is not essential for priming
against fluMP since neutralizing Abs do not block the de-
velopment of specific T cells. However, we show that en-
hanced production of IL-12 or IL-23 by CD40L+IL-1-
activated DC mediates the enhancing effects on the prim-
ing of CD8+ T cell responses.
Conclusions
Altogether, we predict that CD40L+IL-1-treated DC will
function as effective vaccines for the induction of cellular
immunity in vivo. As we see that various degrees of pro-in-
flammatory functional differentiation can be acquired by
DC, it seems that the rational use of adjuvants based on
molecular regulation of cytokines in DC may yield useful
vaccines for immunotherapy.
Methods
Source of cells
Human blood samples were obtained with approval from
the Institutional Review Board of Wayne State University.
G-CSF mobilized peripheral blood was obtained from
breast cancer patients at the Karmanos Cancer Institute.
Cord blood samples were obtained from Hutzel Hospital,
Detroit MI. Mononuclear cells (MNC) were isolated by
centrifugation over Ficoll (Amersham Pharmacia Biotech,
Piscataway, NJ) (d < 1.077 g/ml) and were cryopreserved
in liquid nitrogen using a 10% DMSO freezing solution.
Culture of DC
Monocytes were obtained by incubating MNC on tissue
culture plates (2  106 cells per ml per well in 24 well
plates) in RPMI medium with 10% fetal bovine serum
(FBS) (R10) [35] in a humidified atmosphere at 37C, 5%
CO2 for 2 hours, followed by washing to remove non-ad-
herent cells. These adherent cells were cultured in R10 me-
dium with GM-CSF (25 ng/ml, Immunex, Seattle, WA),
and IL-4 (100 U/ml, kind gift from Dr. H Yssel, DNAX Re-
search Institute, Palo Alto, CA) to induce DC differentia-
tion.
DC activation
Following 6 days of culture, cells were harvested and
washed twice in cytokine-free medium, prior to incuba-
tion with stimuli such as: human recombinant CD40L
trimer (1 g/ml; kind gift of Immunex), IL-1 (10 ng/ml,
unless stated otherwise; Biological Resource Branch Re-
pository, Rockville, MD), LPS (100 ng/ml; Sigma, St. Lou-
is MO), IFN- (100 ng/ml; R&D Systems), IL-1 (various
concentrations; R&D Systems), IL-18 (various concentra-
tions; R&D Systems), TNF- (50 ng/m; RDI, Flanders, NJ).
To measure intracellular cytokine production, monensin
(2 M; Sigma) was added to the DC culture for the last 5
hours. To measure cytokine secretion by ELISA, superna-
tants were collected after 24 hours and stored frozen at -
20C until tested. Endotoxin levels in working concentra-
tions of cytokines, media and CD40L were determined to
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be less than 0.01 ng/ml by Limulus amoebocyte lysate gel
assay (Sigma).
Immuno-staining and flow cytometric analysis
Intracellular staining was done as previously described
[14], Briefly, after fixation in 4% formaldehyde, cells were
washed twice in PBS then permeabilized in saponin buffer
(0.1% saponin (Sigma), 0.2% BSA, 0.02% sodium azide,
in PBS). Non-specific Fc binding was blocked by incuba-
tion for 10 min. on ice with excess human gamma-globu-
lin in saponin buffer (1 mg/ml; Gamimune, Miles,
Eckhert, IL), then cells were incubated for 30 minutes on
ice with mAbs diluted in saponin buffer followed by 2
washes in saponin buffer. Cells were resuspended in wash
buffer without saponin prior to analysis. FITC or APC-
conjugated anti-IL-12 (BD-PharMingen), which recogniz-
es the IL-12 -chain either alone or in IL-12 / het-
erodimer, was used for detection of intracellular IL-12 in
DC, while PE-conjugated anti-IFN- (clone 4S.B3,
Pharmingen) were used for measuring intracellular IFN-
by DC or T cells. Irrelevant control mAbs were used as neg-
ative controls of non-specific staining. Cells were analyzed
on a FACSCalibur instrument (Becton Dickinson) and
data were analyzed using WinMDI (Version 2.8) software.
ELISA
IFN- was measured in supernatants using the OptEIA ELI-
SA set for IFN- according to manufacturer's instructions
(BD-PharMingen). The lower limit of detection was 4 pg/
ml.
Non-isotopic RNase protection assay (RPA)
Following activation with various stimuli for 8 hours (un-
less otherwise indicated), total RNA was isolated from DC
using RNA Isolator (Sigma-Genosys, The Woodlands, TX).
Biotin labeled RNA probes were transcribed from
PharMingen's Multi-Probe template set using Maxiscript
transcription kit (Ambion Inc., Austin, TX) withT7 RNA
polymerase and biotin-14-CTP (Gibco-BRL, Rockville,
MD) used at a 40:60 ratio with unlabeled CTP. RPAs were
performed using Ambion's RPA III kit according to manu-
facturer's instructions. Briefly, sample RNA was hybrid-
ized to 8 ng biotin-labeled probes overnight at 56C, then
digested with RNase A/T. Digested probes were analyzed
on a 8 M urea/5% polyacrylamide gel
(19:1acrylamide:bis-acrylamide, (BioRad, Hercules, CA))
in TBE. Separated probes were transferred to a positively
charged nylon membrane by a semi-dry electroblotter
(Owl Separation Systems, Portsmouth, NH), UV cross-
linked (Stratagene, La Jolla, CA), then subjected to chemi-
luminescent detection using Ambion's BrightStar Biode-
tect kit with CDP-Star substrate. Membranes were exposed
either to Kodak Biomax ML film, or directly to the Kodak
Image station 440 CF for a one-hour capture. Images anal-
ysis was performed using the Kodak Image station 440 CF
and 1D Image Analysis software. Results are expressed as
the ratio of net signal intensity for a particular mRNA to
the net signal intensity of the L32 housekeeping gene.
Immunoprecipitation and western analysis
DC supernatants were concentrated by centrifugation
through YM-10 concentrators (Millipore Corp., Bedford,
Massachusetts) then immunoprecipitated with anti-IL-
12 (C8.6, PharMingen) and A/G agarose bead conjugates
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Precip-
itants were separated by 10% SDS-PAGE under non-re-
ducing conditions, transferred to PVDF membrane, and
blotted with anti-IL-12p70-specific rat monoclonal Ab
20C2 (PharMingen) or anti-IL-12 goat polyclonal Ab
(R&D Systems). HRP-conjugated goat-anti-rat or donkey-
anti-goat polyclonal secondary Abs were visualized using
the ECL detection system (Amersham Biosciences, Piscat-
away, NJ). Blots were exposed to Biomax ML film as
above.
Blocking with neutralizing antibodies
To examine the effects of IL-1ra on DC activation, goat
anti-human neutralizing IgG specific for IL-1Ra (R&D Sys-
tems) and normal goat IgG (R&D Systems) were added at
the start of DC stimulation with CD40L. To examine the
effects of IL-12 in priming experiment 4, polyclonal neu-
tralizing Abs to IL-12 ((R&D Systems) or normal goat IgG
(1 g/ml), were added in the T cell/DC culture at initia-
tion of priming.
Naïve CD8+ T cell priming
DC, prepared from HLA-A2+ cord blood (CB) MNC, were
activated overnight as described above, then pulsed with
10 g/ml influenza matrix peptide Flu-MP (58–66
GILGFVTL; Genemed Synthesis, San Francisco, CA). Au-
tologous purified T cells were obtained by negative selec-
tion, using mAbs specific for CD14 (3C10), CD40
(G28.5), CD32 (IV-3), CD11b (OKM1), glycophorin A
(10F7MN) (ATCC), and HLA-DP/DQ (SPVL-3) (kind gift
of Dr. H Yssel), followed by incubation with sheep anti-
mouse magnetic beads (Dynal, Lake Success, NY). Cells
were further depleted with mAbs to HLA-DR and CD16
(Caltag) and a second round of selection with beads. The
resulting cell preparations contained > 95% CD3+ T cells.
Peptide pulsed-DC were irradiated (400-cGy 137Cs
source), washed twice, then incubated with purified T
cells in R10 medium supplemented with 10 ng/ml IL-7
(R&D Systems) at 37C, 5% CO2. Cultures were replen-
ished with R10 and IL-7 on day 3–4 by demi-depletion,
and were examined for the presence of antigen specific
cells by flow cytometry on day 7. Briefly, T cells were
counted then incubated in the dark at 37C for 15 min.
with APC-labeled Flu-MP-HLA-A2 tetramer constructs
(NIAID Tetramer Facility and the NIH AIDS Research and
Reference Reagent Program, Atlanta, GA). After washing,
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cells were incubated with anti-CD8-FITC (OKT8, ATCC,
conjugated in our lab) and anti-CD45RA-PE (Caltag)
mAbs, then washed. Cells were resuspended with 5 g/ml
propidium iodide (Sigma) for exclusion of dead cells and
analyzed by flow cytometry. The limit of detection of
CD8+ Flu-MP-HLA-A2 tetramer+ T cells was 0.02–0.04%
as determined by dilutions of a flu-MP specific HLA-A2+ T
cell line in HLA-A2- cord blood MNC. Negative control
consisted of HLA-A2- cord blood MNC in which < 0.01%
(n = 3) CD8+ Flu-MP-HLA-A2 tetramer+ cells were detect-
ed. Percent of CD8+ cells binding Flu-MP-HLA-A2 tetram-
er were calculated by setting quadrants based on staining
with isotype control Abs (staining <0.01%), and calculat-
ed as (% Flu-MP-HLA-A2 tetramer+ CD8+ cells) / (% total
CD8+ cells). Absolute number of tetramer+ cells was cal-
culated as (% CD8+ Flu-MP-HLA-A2 tetramer+ cells)  (to-
tal number of cells in culture after priming). Fold
expansion specific T cells was calculated as (absolute
number of tetramer+ cells after priming) / (absolute
number of tetramer+ cells in initiating cultures).
Mixed lymphocyte reaction (MLR)
The procedure has been described elsewhere [14]. Briefly,
preparations >90% pure T cells were obtained from MNC
by removal of cells recognized by mAbs to CD14 (3C10),
CD40 (G28.5), CD32 (IV-3), CD11b (OKM1), glycoph-
orin A (10F7MN), (ATCC, Manassas, VA) HLA-DP/DQ
(SPVL-3, kind gift of Dr. H Yssel) and CD16 (KD1, kind
gift of Dr. Ferlazzo, Istituto Nazionale per la Ricerca sul
Cancro, Genoa, Italy), HLA-DR and CD15 (Caltag) using
indirect panning on goat-anti-mouse IgG (Sigma)-coated
plates, followed by a second round of negative selection
with sheep anti-mouse magnetic beads (Dynal, Lake Suc-
cess, NY). Populations of CD4+ or CD8+ T cells were ob-
tained by removing the opposite subset in the second
round of purification. Allogeneic DC were irradiated and
cultured with pure T cells at the concentration of 20%
DC:T cell ratio in R10 medium for 8 days. On day 8, su-
pernatant fluids were collected to measure cytokine con-
tent by ELISA and cells were harvested to be re-stimulated
for 5 hours on plates coated with mAbs to CD3 and CD28
(2 g/ml each) (PharMingen, San Diego, CA). Monensin
(2 M; Sigma) was added to enable the detection of intra-
cellular IFN- by flow cytometry.
RT-PCR
Total RNA prepared from DC was reverse transcribed after
incubation with Superscript II reverse transcriptase (Gib-
co) and random hexanucleotide primers for one hour at
37C. The resulting cDNA was amplified by PCR using
AmpliTaq DNA polymerase (Applied Biosystems (PE
Corp), Foster City, CA) and primers for p19 (forward: 5'
AGC AGC TCA AGG ATG GCA CTC AG 3'; reverse: 5' CCC
CAA ATT TCC CTT CCC ATC TA 3') and for 18S ribosomal
RNA (Ambion) for 35 cycles (1 min 95C, 2 min 56C, 1
min 70C). PCR products were separated on a 2% agarose
gel, stained with ethidium bromide.
Statistical analysis
Paired t-Test analysis was used to assess statistical differ-
ences where indicated.
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